Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany

Background Cardiovascular disease is the leading cause of mortality in Germany. Cardiovascular risk can be mitigated with long-term lipid-lowering therapies (LLTs) that reduce levels of low-density lipoprotein cholesterol. Although effective, risk mitigation is hindered by poor persistence and adherence.Objective To investigate real-world persistence and adherence to LLTs through 36 months post-initiation.Methods This retrospective cohort study included patients with dyslipidemia who were newly prescribed LLTs between July and December 2017, using anonymized prescription data from the Insight Health (TM) Patient Insight Tool, and followed up until March 2021. Persistence and adherence to the therapies were stratified by age and sex. The proportion of days covered (PDC) was used to measure adherence.Results Patients with dyslipidemia and newly prescribed statins (n = 865,732), ezetimibe (n = 34,490), or anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (anti-PCSK9 mAbs; n = 1940) were included. Persistence to LLTs declined gradually across all treatment subgroups and was lower in women than men. Adherence, calculated as the mean PDC at the end of the analysis period (July 2017-March 2021) was 0.84, 0.92, and 0.93 for statins, ezetimibe, and anti-PCSK9 mAbs, respectively. Among patients who discontinued treatment, mean treatment duration was 265, 255, and 387 days for statins, ezetimibe, and anti-PCSK9 mAbs, respectively. Only similar to 10% of patients persisted between 201 and 300 days. By Day 300, 71% of patients on statins had discontinued treatment. At 36 months, overall persistence rates were lowest with statins (20.6%), followed by ezetimibe (22.3%) and anti-PCSK9 mAbs (50.9%).Conclusions High non-persistence rates were observed across all LLT regimens analyzed, with the lowest persistence rates observed with statins.

Automated summary

This study investigated the real-world persistence and adherence to lipid-lowering therapies in German patients with cardiovascular disease. The findings showed low persistence and adherence rates, especially in women. The study also found that patients who discontinued treatment had a relatively short average treatment duration, and only about 10% of patients persisted in medication for more than 300 days. Overall, the persistence rates with lipid-lowering therapies were low at 36 months.